Bellerophon Therapeutics Inc
F:6L7A
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
B
|
Bellerophon Therapeutics Inc
F:6L7A
|
3.7m EUR |
Loading...
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
187.1B USD |
Loading...
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
184.5B USD |
Loading...
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
139.3B USD |
Loading...
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
136.2B USD |
Loading...
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
129.3B USD |
Loading...
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
57.8B USD |
Loading...
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
47.6B EUR |
Loading...
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
55.2B USD |
Loading...
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
47.9B USD |
Loading...
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
37.5B USD |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Bellerophon Therapeutics Inc
Glance View
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Bellerophon Therapeutics Inc is -194.1%, which is above its 3-year median of -210.7%.
Over the last 6 months, Bellerophon Therapeutics Inc’s Net Margin has increased from -218.5% to -194.1%. During this period, it reached a low of -240% on Jun 30, 2023 and a high of -173.5% on Oct 30, 2023.